Arthur A. Patchett

13.0k citations

126 papers · 6.7k indexed · 1 hit paper · h-index 39

Molecular Biology top 2%
Organic Chemistry top 1%
Endocrine and Autonomic Systems top 0.5%
Endocrinology, Diabetes and Metabolism top 1%
Pharmacology top 1%

Co-authors: Ravi P. Nargund Matthew J. Wyvratt William J. Greenlee Scott D. Feighner Roy G. Smith Gerard J. Hickey Lex H.T. Van der Ploeg H Joshua
Topics: Growth Hormone and Insulin-like Growth Factors (26 papers)Chemical Synthesis and Analysis (22 papers)Receptor Mechanisms and Signaling (20 papers)
Cited by: Endocrine and Autonomic Systems Biotechnology Endocrinology, Diabetes and Metabolism
Journals: Nature Science Proceedings of the National Academy of Sciences
Partner nations: United States Japan Germany

In The Last Decade

Arthur A. Patchett

125 papers receiving 6.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent.

1980 1.3k citations Arthur A. Patchett, Otto D. Hensens et al. profile →

Peers

Countries citing papers authored by Arthur A. Patchett

Since Specialization

Citations

This map shows the geographic impact of Arthur A. Patchett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arthur A. Patchett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arthur A. Patchett more than expected).

Fields of papers citing papers by Arthur A. Patchett

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arthur A. Patchett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arthur A. Patchett. The network helps show where Arthur A. Patchett may publish in the future.

Co-authorship network of co-authors of Arthur A. Patchett

This figure shows the co-authorship network connecting the top 25 collaborators of Arthur A. Patchett. A scholar is included among the top collaborators of Arthur A. Patchett based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arthur A. Patchett. Arthur A. Patchett is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Melanocortin subtype 4 receptor agonists: Structure–activity relationships about the 4-alkyl piperidine core 2006 ·Bioorganic & Medicinal Chemistry Letters ·Iyassu K. Sebhat,Yingjie Lai,Khaled Barakat,Zhixiong Ye,Rui Tang,Rubana N. Kalyani,Aurawan Vongs,Tanya MacNeil,David H. Weinberg,M. Angeles Cabello,Marta Maroto,Ana Teran,Tung M. Fong,Lex H.T. Van der Ploeg,Arthur A. Patchett,Ravi P. Nargund	2
2	Optimization of a privileged structure leading to potent and selective human melanocortin subtype-4 receptor ligands 2005 ·Bioorganic & Medicinal Chemistry Letters ·Raman K. Bakshi,Qingmei Hong,Rui Tang,Rubana N. Kalyani,Tanya MacNeil,David H. Weinberg,Lex H.T. Van der Ploeg,Arthur A. Patchett,Ravi P. Nargund	12
3	Lewis Hastings Sarett, December 22, 1917 - November 29, 1999. 2002 ·PubMed ·Arthur A. Patchett	3
4	Angiotensin-converting enzyme inhibitors 2001 ·Advances in protein chemistry ·Joël Ménard,Arthur A. Patchett	41
5	Modeling directed design and biological evaluation of quinazolinones as non-peptidic growth hormone secretagogues 2000 ·Bioorganic & Medicinal Chemistry Letters ·Zhixiong Ye,(unknown),Raman K. Bakshi,Meng‐Hsin Chen,Susan P. Rohrer,Scott D. Feighner,Sheng‐Shung Pong,Andrew D. Howard,Allan D. Blake,Elizabeth T. Birzin,Louis Locco,Rupa M. Parmar,Wanda Chan,James M. Schaeffer,Roy G. Smith,Arthur A. Patchett,Ravi P. Nargund	19
6	Thiazole-derived potent, highly bioavailable short duration growth hormone secretagogues 1999 ·Bioorganic & Medicinal Chemistry Letters ·Lihu Yang,(unknown),Kwan Leung,Tom Jacks,Kang Cheng,Klaus D. Schleim,Roy G. Smith,Arthur A. Patchett	4
7	Synthesis and biological activities of spiroheterocyclic growth hormone secretagogues 1999 ·Bioorganic & Medicinal Chemistry Letters ·Meng‐Hsin Chen,(unknown),Arthur A. Patchett,Kang Cheng,(unknown),Wanda Chan,Bridget Butler,Thomas M. Jacks,Roy G. Smith	28
8	Tripeptide growth hormone secretagogues 1998 ·Bioorganic & Medicinal Chemistry Letters ·Lihu Yang,(unknown),Yanping Pan,Ravi P. Nargund,Khaled Barakat,Kristine Prendergast,(unknown),Wanda Chan,R G Smith,Arthur A. Patchett	8
9	Synthesis and biological activities of phenyl piperazine- based peptidomimetic growth hormone secretagogues 1998 ·Bioorganic & Medicinal Chemistry Letters ·Khaled J. Barakat,(unknown),Wanda Chan,(unknown),Thomas M. Jacks,Klaus D. Schleim,(unknown),Gerard J. Hickey,R G Smith,Arthur A. Patchett,Ravi P. Nargund	15
10	Repeat administration of the GH secretagogue MK-0677 increases and maintains elevated IGF-I levels in beagles 1997 ·Journal of Endocrinology ·Gerard J. Hickey,Thomas M. Jacks,Klaus D. Schleim,Easter G. Frazier,(unknown),David Krupa,William P. Feeney,Ravi P. Nargund,Arthur A. Patchett,R G Smith	38
11	In vivo pharmacology of a novel AT selective angiotensin II receptor antagonist, MK-996 1995 ·American Journal of Hypertension ·Salah D. Kivlighn,Gloria J. Zingaro,Robert A. Gabel,Theodore P. Broten,Terry W. Schorn,L W Schaffer,Elizabeth M. Naylor,Probir Chakravarty,Arthur A. Patchett,William J. Greenlee	10
12	Structural model of antagonist and agonist binding to the angiotensin II, AT1 subtype, G protein coupled receptor 1994 ·Chemistry & Biology ·Dennis Underwood,Catherine D. Strader,Ralph A. Rivero,Arthur A. Patchett,William J. Greenlee,Kristine Prendergast	55
13	Non-peptide angiotensin II receptor antagonists. 1. Design, synthesis, and biological activity of N-substituted indoles and dihydroindoles 1993 ·Journal of Medicinal Chemistry ·(unknown),Scott W. Bagley,Raymond S.L. Chang,Victor J. Lotti,(unknown),Salah D. Kivlighn,Gloria J. Zingaro,Peter K. S. Siegl,Arthur A. Patchett,William J. Greenlee	24
14	A potent, orally active, balanced affinity angiotensin II AT1 antagonist and AT2 binding inhibitor 1993 ·Journal of Medicinal Chemistry ·Stephen E. de Laszlo,(unknown),William J. Greenlee,Arthur A. Patchett,Raymond S.L. Chang,Victor J. Lotti,(unknown),(unknown),(unknown)	102
15	Analogs of cyclosporin A modified at the D-Ala8 position. 1992 ·The Journal of Antibiotics ·Arthur A. Patchett,D. Taub,Otto D. Hensens,Robert T. Goegelman,Lihu Yang,Francis J. Dumont,(unknown),N H Sigal	12
16	Design and synthesis of P2-P1'-linked macrocyclic human renin inhibitors 1991 ·Journal of Medicinal Chemistry ·Ann E. Weber,Thomas A. Halgren,John Doyle,Robert J. Lynch,Peter K. S. Siegl,William H. Parsons,William J. Greenlee,Arthur A. Patchett	40
17	Design of a selective insulin receptor tyrosine kinase inhibitor and its effect on glucose uptake and metabolism in intact cells 1989 ·Biochemistry ·Richard Saperstein,Pasquale P. Vicario,H.V. Strout,Edward J. Brady,Eve E. Slater,William J. Greenlee,Debra L. Ondeyka,Arthur A. Patchett,David Hangauer	96
18	(3-Amino-2-oxoalkyl)phosphonic acids and their analogs as novel inhibitors of D-alanine:D-alanine ligase 1989 ·Journal of Medicinal Chemistry ·Prasun K. Chakravarty,William J. Greenlee,William H. Parsons,Arthur A. Patchett,(unknown),(unknown),R.D. Busch,T.N. Mellin	88
19	The Design and Properties of N‐Carboxyalkyldipeptide Inhibitors of Angiotensin‐Converting Enzyme 1985 ·Advances in enzymology and related areas of molecular biology/Advances in enzymology and related subjects ·Arthur A. Patchett,Eugene H. Cordes	87
20	Structure-activity studies with angiotensin converting enzyme inhibitors related to enalapril and MK-521. 1984 ·Charles S. Sweet,Arthur A. Patchett,(unknown),Dennis M. Gross	1

About Arthur A. Patchett

Arthur A. Patchett is a scholar working on Endocrinology, Diabetes and Metabolism, Endocrine and Autonomic Systems and Biochemistry, having authored 126 papers that have together received 6.7k indexed citations. Recurring topics across this work include Growth Hormone and Insulin-like Growth Factors (26 papers), Chemical Synthesis and Analysis (22 papers) and Receptor Mechanisms and Signaling (20 papers). The work is most often cited by research in Endocrine and Autonomic Systems (1.1k citations), Biotechnology (808 citations) and Endocrinology, Diabetes and Metabolism (924 citations). Arthur A. Patchett has collaborated with scholars based in United States, Japan and Germany. Frequent co-authors include Ravi P. Nargund, Matthew J. Wyvratt, William J. Greenlee, Scott D. Feighner, Roy G. Smith, Gerard J. Hickey, Lex H.T. Van der Ploeg, H Joshua, Susan D. Aster and Otto D. Hensens. Their work appears in journals such as Nature, Science and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact